Valesca Retel
Valesca is endowed professor at the Erasmus University of Rotterdam, where she has a research chair called “HTA in translational research in oncology”. This chair has 3 pillars:
- Affordability
- Sustainability
- Timeliness
Valesca is endowed professor at the Erasmus University of Rotterdam, where she has a research chair called “HTA in translational research in oncology”. This chair has 3 pillars:
Dissertation Nora Franzen
Affordable prices of innovative anticancer medicines are indispensable in enabling patients to receive the most suitable treatment. The prices of many pharmaceutical treatments are, presumably, leading to healthcare budgets approaching capacity limits globally, including in high-income countries. Anticancer treatments account for the largest cost category in specialized medical care. Strategies are needed to assure the affordability of medicines and sustainability of healthcare systems without compromising pharmaceutical innovation. This dissertation explores evidenced-based interventions that lead to affordable medicine prices in oncology at market launch in high-income European countries.
Dissertation Melanie Lindenberg
Healthcare budgets are under pressure because of increasing healthcare costs, resulting in an increased awareness that money has to be spent wisely. Therefore, health innovations need to prove their value for money before they will be implemented in the hospital. Health technology assessments (HTA) can be used to systematically assess the effects, among others the cost-effectiveness, of a new technology of interest.
This website uses cookies to ensure you get the best experience on our website.
